New kidney drug PMG1016 enters first human safety trial
NCT ID NCT07615985
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tests a new drug called PMG1016 in 30 healthy adults to see if it is safe and how the body processes it. The drug is given as a single IV infusion. This is the first time PMG1016 is being tested in humans, and it aims to gather safety data before moving to patient studies for chronic kidney disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PMG1016
- What this could lead to
- If safe, this could lead to a new treatment for chronic kidney disease, helping control the condition.
- What could go wrong
- This is a very early, small Phase 1 trial in healthy people, not patients. It only tests safety, not effectiveness. Many drugs fail at this stage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nucleus Network (Brisbane)
Brisbane, Queensland, 4006, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Aging kidneys under the microscope: could a simple test predict failure?
- Could your gut bacteria hold the key to protecting your kidneys?
- Food as medicine: could cooking classes slow kidney disease?
- Could a phone app be the key to managing kidney disease?
- A new pill aims to slow kidney failure and save lives
- AI takes on kidney disease: a new model to forecast Who's at risk